glp-1 options for type 2 diabetes and obesity 2025 New Guidelines in GLP-1 agonists and changes in

1.2 Safety considerations and the limits of the GLP-1 analogy The success of GLP-1 receptor agonists should not obscure legitimate safety considerations associated with chronic peptide therapy

For example, insulin resistance is emerging as a key indicator of Alzheimers disease and Parkinsons disease

a direct causal link in humans has not been established, but patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should avoid this class of medicine [16] [17] Gallbladder disease rapid weight loss can increase the risk of gallstones and gallbladder inflammation [25] [26] Diabetic retinopathy rapid improvement in glycaemic control has been associated with worsening of diabetic retinopathy in people with pre-existing disease

Identification of a mutation in the ileal sodium-dependent bile acid transporter gene that abolishes transport activity (*)

The standard schedule is: Week one: 1 tablet in the morning Week two: 1 tablet in the morning and one in the evening Week three: 2 tablets in the morning and one in the evening Week four and beyond: 2 tablets in the morning and two in the evening You should swallow tablets whole and avoid taking Contrave with high fat meals, as this can increase the drug levels in your body and increase your risk of seizures

Never share injection pens or devices with others, even if the needle has been changed, as this poses serious infection risks